NIH to Feinstein: Stick out that chest (bioelectrically)
By GREGORY ZELLER // With new treatments for obesity, heart failure and a host of other conditions in sight, a Feinstein Institute researcher will zero in on specific abdominal targets…
Sanguistat
No. 324: Vikings on Mars, FSC on the job, Sanguistat on the move, and why Freeport is happy to be on the outs
Well done: Very impressive, intrepid reader – you’ve made it to the end of another productive workweek, and earned yourself another glorious weekend. It’s July 20 out there, and if…
Nerve-stim startup Sanguistat shuffles its deck
By GREGORY ZELLER // A Connecticut-based biotech spun out of the Feinstein Institute for Medical Research has assembled a powerful collection of advisors and directors, including corporate heavyweights and recognized…
Nerves of steel: Sanguistat stimulator steps up
By GREGORY ZELLER // The world’s leading cause of maternal deaths is the target of new clinical trials for a trailblazing bioelectronic medical device. The Neural Tourniquet, an electronic nerve-stimulation…
Feinstein’s Tracey to head bioelectronics summit
Feinstein Institute chief and global bioelectronics pioneer Kevin Tracey will headline a September New York Academy of Science conference on bioelectronic medicine. Tracey, Feinstein’s president and CEO and the brains…
Feinstein launching Neural Tourniquet as newco
By GREGORY ZELLER // Meet Sanguistat, the corporate face of the latest technology spinning out of Northwell Health’s Feinstein Institute for Medical Research. For now, Sanguistat is not an Inc….